Chemotherapy of Acute Leukemia: A Comparison of Vincristine, Cytarabine, and Prednisone Alone and in Combination With Cyclophosphamide or Daunorubicin

Charles A. Coltman, Gerald P. Bodey, James S. Hewlett, Arthur Haut, John Bickers, Stanley P. Balcerzak, John J. Costanzi, Emil J. Freireich, Kenneth B. Mccredie, Carl Groppe, Terry L. Smith, Edmund A. Gehan

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Adults (274) with acute leukemia (AML) were randomly assigned to one of three treatment regimens: vincristine, prednisone, cytarabine—(1) 100 mg/sq m/day with cyclophosphamide (COAP); (2) 100 mg/sq m/day with daunorubicin (DOAP); and 200 mg/sq m/day (OAP). Cytarabine was infused continuously for five days. Patients entering complete remission randomly received maintenance treatment with COAP or OAP. For 197 previously untreated AML patients given COAP, DOAP, or OAP, remission rates were 37%, 35%, and 43%, respectively; median lengths, 40, 45, and 90 weeks; median survival, 7, 11, and 8 weeks. No statistically significant difference was found among treatments. Therefore, adding cyclophosphamide or daunorubicin, or using the COAP regimen with continuously infused cytarabine, produced no significant improvement over previously reported regimens. There was no significant difference in remission lengths in previously untreated AML patients maintained on OAP (median 81 weeks) or COAP (median 65 weeks).

Original languageEnglish (US)
Pages (from-to)1342-1348
Number of pages7
JournalArchives of Internal Medicine
Volume138
Issue number9
DOIs
StatePublished - Sep 1978
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Chemotherapy of Acute Leukemia: A Comparison of Vincristine, Cytarabine, and Prednisone Alone and in Combination With Cyclophosphamide or Daunorubicin'. Together they form a unique fingerprint.

Cite this